All research
Human randomized trial / 2019
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials
Kingsberg SA, Clayton AH, Portman D, et al.
Study overview
Two phase 3 trials evaluated premenopausal women with hypoactive sexual desire disorder. Desire and distress measures improved versus placebo, while satisfying sexual events did not differ significantly.
Results are specific to the study. This is an editorial summary, not personal treatment advice.
Study limitations
The studied indication and population are specific. Nausea was common. The results cannot be generalized into a performance-enhancement recommendation or to unregulated PT-141 products.
About this summary
This summary uses the cited abstract and bibliographic record. Read the original methods and results for the full context.